RE-BVS – Piemonte Repository

Sfoglia per AUTORE
FOLLADOR A
Collezione AOU San Luigi di Orbassano

Items : 7

Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2024 May;202:114006. doi: 10.1016/j.ejca.2024.114006. Epub 2024 Mar 11.

2024
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Salerno F; Camerini A; Carta A; Follador A; Berardi R; Toschi L; Zoratto F; Cortinovis DL; Citarella F; Bulotta A; Rastelli F; Adamo V; Guida A; Manzo A; Cecere FL; Belluomini L; Roca E; Pasello G; Cerea G; Montrone M; Delcuratolo MD; Passiglia F; Guaitoli G; Bertolini F; Genova C; Caliman E; Mazzoni F; Siringo M; Gelibter A; et alii...

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Scagliotti GV; Porcu L; Manegold C; Monica V; Wiest G; Irtelli L; Caffo O; Dickgreber NJ; Follador A; Pedrazzoli P; Bearz A; Griesinger F; Folprecht G; Schmid-Bindert G; Reck M; Chiari R; Gregorc V; Santo A; Morabito A; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Apr;33(4):454. doi: 10.1016/j.annonc.2022.01.005. Epub 2022 Jan 25.

2022
AO Cuneo
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Porcu L; Manegold C; Scagliotti GV; Monica V; Wiest G; Irtelli L; Dickgreber NJ; Caffo O; Pedrazzoli P; Bearz A; Folprecht G; Griesinger F; Follador A; Chiari R; Reck M; Morabito A; Santo A; Schmid-Bindert G; Gregorc V; Schena M; Valmadre G; Borra G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Cauchi C; Colantonio I; Geissler M; Meyer A; et alii...

Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study. in Thoracic cancer / Thorac Cancer. 2021 Mar;12(6):880-889. doi: 10.1111/1759-7714.13852. Epub 2021 Feb 1.

2021
AOU San Luigi di Orbassano

Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; et alii...

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Jun;150:224-231. doi: 10.1016/j.ejca.2021.03.041. Epub 2021 May 3.

2021
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Novara

Cortellini A; Mazzaschi G; Tiseo M; Pinato DJ; Carmisciano L; Ficorella C; Porzio G; Cannita K; Friedlaender A; Addeo A; Banna GL; Spinelli GP; Adamo V; Russo A; Olmetto E; Metro G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Minuti G; Tuzi A; Bisonni R; Follador A; Gelibter A; Siringo M; Signorelli D; De Toma A; Garassino MC; et alii...

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ? 50% and Their Relationship With Clinical Outcomes. in Clinical lung cancer / Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.cllc.2020.06.010. Epub 2020 Jun 21.

2020
AOU San Luigi di Orbassano

Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; et alii...

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study. in Lung cancer (Amsterdam, Netherlands) / Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26.

2016
AOU San Luigi di Orbassano

Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S;